Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Aug. 26, 2026—The Food and Drug Administration today approved daraxonrasib (Rasonque, Revolution Medicines) for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
August 2026—Testing for homologous recombination deficiency (HRD) is not for the faint of heart. Even the experts agree. Tricia Numan, MD, says that when she first became involved in the topic, “I didn’t realize how many components went into HRD testing,” including germline alterations, somatic alterations, and various classifications of genomic instability.
August 2026—In a summer of more ticks, more diseases, and more tick species expanding to new areas and bringing diseases with them, what Bobbi Pritt, MD, MSc, would like to see are more—and better—diagnostics in early Lyme disease. Laboratory scientists are inching toward improved solutions, though nothing is commercially available now. “I’m cautiously optimistic. I wouldn’t say I’m excited yet,” says Dr. Pritt, co-director of vector-borne diseases laboratory services and chair of the Division of Clinical Microbiology at Mayo Clinic in Rochester.
August 2026—Recognizing and reporting histologic subtypes and divergent differentiation in urothelial carcinoma is critical for diagnosis, prognosis, and treatment. “Ideally, you want to mention the subtype histologies in pathology reports and quantify the amount,” said Francesca Khani, MD, associate professor in the Department of Pathology and Laboratory Medicine and in the Department of Urology, Weill Cornell Medicine. In a CAP25 session last fall, Dr. Khani spoke of the mimics of benign entities and of other malignancies.
August 2026—Would artificial intelligence as an aid in ordering laboratory tests and making reports understandable to patients be a worry or a welcome step? In a June 2 online roundtable led by CAP TODAY publisher Bob McGonnagle, a Compass Group member shared what he learned about an Epic pilot, and that launched the following conversation about the clinical laboratory and pathology reports that could be made easier for patients to understand. One participant’s view: “proceed with caution.”
August 2026—A series of hands-on or role-playing workshops created by pathology student interest group leaders at a California medical school introduced pathology to dozens of students who would have otherwise completed their curriculum without that exposure.
August 2026—The 2022 World Health Organization and International Consensus Classification frameworks recognize several well-defined myeloid neoplasm categories that arise in the setting of inherited genetic predisposition. These entities are grouped according to associated clinical features and include myeloid neoplasms with germline predisposition in the absence of antecedent platelet abnormalities or organ dysfunction (e.g. CEBPA, DDX41, and TP53), those associated with inherited platelet disorders (e.g. RUNX1, ANKRD26, and ETV6), and disorders linked to underlying or potential organ dysfunction.
August 2026—Although cytologists and cytopathologists expend considerable effort in screening, risk stratification, diagnosis, staging, and prognostication, clinicians are increasingly demanding ancillary testing that predicts response or resistance to the broad range of therapeutic agents available to them. In advanced-stage non-small cell lung carcinoma, these therapies include tyrosine kinase and other small-molecule inhibitors, bispecific antibodies, and antibody-drug conjugates.
August 2026—Pediatric pathology remains a relatively small subspecialty within anatomic pathology. The American Board of Pathology since 1990 has issued only 648 subspecialty certificates in pediatric pathology, and between 2020 and 2024, only 14 to 21 candidates sat for the pediatric pathology certifying examination each year.
August 2026—Cytology specimens have long played a central role in primary diagnosis, with fine-needle aspiration often serving as the first—and sometimes only—procedure performed before treatment decisions are made. However, when molecular testing is needed, cytology material is still often viewed through a histology-centered lens: Is there a cell block or core biopsy?
